Literature DB >> 7214602

In vivo study on alkylation site in DNA by the bifunctional dianhydrogalactitol.

E Institoris.   

Abstract

In vivo alkylation of Yoshida sarcoma cell DNA by 3H-labelled 1,2:5,6-dianhydrogalactitol (DAG) yielded N-7 monogalactitylguanines and 1,6-di-(guanin-7-yl)-galactitol, similar to the alkylated products obtained by in vitro reaction of DNA with dianhydrogalactitol in neutral solution. The ratio between monoalkylguanines and diguaninyl product was 2-2.5, slightly increasing with doses. Persistence of alkylated products in DNA was followed in function of time. There was no significant loss of either monoalkylated bases or diguaninyl derivative during the observation period i.e. 7-24 h after treatment. In contrast, the physical measurements of the amount of renaturable DNA showed a rapid opening of cross-links in the same period. Taking the presence of diguaninyl moiety as an indicator of cross-links in DNA, these two latter findings show an apparent contradiction which could be reconciled however by the mechanism proposed by Reid and Walker (Biochim. Biophys. Acta, 179 (1969) 179) for the removal of cross-linkage induced by HN2. Accordingly, one arm of the cross-links is removed, probably enzymically, leaving the DNA non-renaturable, while the other arm of cross-link is still covalently attached to the DNA molecule rendering possible the detection of diguaninyl moiety in DNA at some later time. This concept for the removal of cross-links from DNA seems to be supported by our results too.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7214602     DOI: 10.1016/0009-2797(81)90144-7

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  4 in total

1.  Benzamide potentiation of the cytotoxicity of bifunctional galactitol [correction of galacticol] in resistant P388 leukemia correlates with inhibition of DNA ligase II.

Authors:  E Institoris; B W Fox; I Pályi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  1,2:5,6-dianhydrogalactitol inhibits human glioma cell growth in vivo and in vitro by arresting the cell cycle at G2/M phase.

Authors:  Chun Peng; Xin-Ming Qi; Ling-Ling Miao; Jin Ren
Journal:  Acta Pharmacol Sin       Date:  2017-02-20       Impact factor: 6.150

3.  Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.

Authors:  E Institóris; K Szikla; L Otvös; F Gál
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination.

Authors:  Beibei Zhai; Anne Steinø; Jeffrey Bacha; Dennis Brown; Mads Daugaard
Journal:  Cell Death Dis       Date:  2018-10-03       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.